新たに診断された神経膠芽腫の治療のためのセツキシマブの超選択的動脈内反復注入
新たに診断された神経膠芽腫の治療のためのセツキシマブの超選択的動脈内反復注入の第I / II相試験
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, afflicting approximately 7,000 patients in the United States each year. These highly malignant cancers remain a significant unmet clinical need in oncology. GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX). The investigators have recently completed a separate Phase I clinical trial using superselective intra-arterial cerebral infusion (SIACI) of CTX after blood brain barrier disruption (BBBD) for recurrent GBM (Chakraborty et al, in revision, Journal of Neurooncology). The investigators found that intra-arterial infusion of CTX is well tolerated with few adverse effects. The investigators hypothesize that in patients with newly diagnosed GBM, repeated SIACI of this drug after BBBD will be safe and efficacious for our patients when combined with standard chemoradiation (STUPP protocol).
This trial will be a non-randomized open label Phase I/II clinical trial. In addition to standard chemotherapy and radiation therapy (STUPP protocol) the patient will be given CTX intra-arterially after BBBD for a total of three doses at approximately post surgery days 30, 120 and 210.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:John Boockvar, MD
- 電話番号:212-434-4836
- メール:jboockvar@northwell.edu
研究連絡先のバックアップ
- 名前:Tamika Wong, MPH
- 電話番号:212-434-4836
- メール:twong4@northwell.edu
研究場所
-
-
New York
-
New York、New York、アメリカ、10075
- 募集
- Lenox Hill Brain Tumor Center
-
コンタクト:
- Tamika Wong, MPH
- 電話番号:212-434-4836
- メール:twong4@northwell.edu
-
コンタクト:
- John Boockvar, MD
- 電話番号:212-434-3900
- メール:jboockvar@northwell.edu
-
副調査官:
- David Langer, MD
-
副調査官:
- Christopher Filippi, MD
-
副調査官:
- Tamika Wong, MPH
-
副調査官:
- Rafael Ortiz, MD
-
副調査官:
- Ashley Ray, NP
-
副調査官:
- Sherese Fralin, NP
-
副調査官:
- Anuj Goenka, MD
-
副調査官:
- Jed Pollack, MD
-
副調査官:
- Karissa Tan, NP
-
副調査官:
- Shamik Chakraborty, MD
-
主任研究者:
- John Boockvar, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female patients of ≥18 years of age.
-
Patients with a documented histologic diagnosis of newly diagnosed glioblastoma multiforme (GBM)
-
Patients with pathology confirmed histologic EGFR overexpression
-
Patients must have at least one confirmed and evaluable tumor site.∗
*A confirmed tumor site is one in which is biopsy-proven. NOTE: Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within two weeks of treatment on this research study.
-
Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level of 0-2) and an expected survival of ≥ three months.
-
No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for eight weeks prior to treatment under this research protocol.
-
Patients must have adequate hematologic reserve with WBC≥3000/mm3, absolute neutrophils ≥1500/mm3 and platelets ≥100,000/ mm3. Patients who are on Coumadin must have a platelet count of ≥150,000/ mm3
-
Pre-enrollment chemistry parameters must show: bilirubin<1.5X the institutional upper limit of normal (IUNL); AST or ALT<2.5X IUNL and creatinine<1.5X IUNL.
-
Pre-enrollment coagulation parameters (PT and PTT) must be ≤1.5X the IUNL.
-
Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.
-
Patients must be able to understand and give written informed consent. Informed consent must be obtained at the time of patient screening.
Exclusion Criteria:
- Women who are pregnant or lactating.
- Women of childbearing potential and fertile men will be informed as to the potential risk of conception while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period.
- Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring
- Patients with radiological evidence of leptomeningeal disease.
- Patients with history of allergic reaction to CTX
- Patients who initiated or completed chemo/RT
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Intra-arterial Cetuximab after BBBD
Mannitol 20% 12.5ml over two minutes for Blood Brain Barrier (BBB) disruption followed by CTX administered intra-arterially for three doses at a dose of 250mg/m2 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:6 months
|
The 6-month PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free. |
6 months
|
|
Overall Survival (OS)
時間枠:2 years
|
OS will be calculated as the time from treatment initiation to the date of death. |
2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO)
時間枠:6 months
|
Subjects will be classified according to the RANO criteria, which is a composite of MRI changes, clinical response and changes in steroid use. |
6 months
|
|
Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
時間枠:6 months
|
Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03 |
6 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。